Botanix Pharmaceuticals: Edison Open House Healthcare 2022

Botanix Pharmaceuticals Limited is an ASX-listed dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of novel treatments for common skin diseases and infections that are underpinned by science and supported by well-controlled, randomised clinical trials.

• Tell us about the dermatology market sector which Botanix targets.
• How does Permetrex, your proprietary skin delivery technology, work and what are the advantages?
• What are the timelines for the development of your rosacea solution?
• How does this influence your other dermatology programmes?
• What are the benefits of using cannabinoids in dermatology?
• How is your Phase III study for acne progressing?
• How are you progressing with regard to the FDA incentives around Staphylococcus aureus infection in hemodialysis patients?
• What is your intellectual property strategy?
• Which milestones should investors focus on in the coming year?
• Can you tell us more about the testing model and has this resulted in faster trials?
• How will these data be used?